Systemic chemotherapy in the management of malignant peritoneal mesothelioma

European Journal of Surgical Oncology

Volumn 32, Issue 6, 2006, Pages 676-681

  Garcia Carbonero, R ^a   Paz Ares, L ^b  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antifolates; Chemotherapy; Mesothelioma; Pemetrexed; Peritoneal

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYTOTOXIC AGENT; DOXORUBICIN; EDATREXATE; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; IMATINIB; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SEMAXANIB; THALIDOMIDE; TRIMETREXATE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE MANAGEMENT; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; MEDLINE; PATIENT CARE; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; DEOXYCYTIDINE; GLUTAMATES; GUANINE; HUMANS; MESOTHELIOMA; PERITONEAL NEOPLASMS; QUINAZOLINES; THIOPHENES; VINBLASTINE;

EID: 33745995453     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.009     Document Type: Article

References (35)

1. Zellos L., and Christiani D.C. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 14 (2004) 469-477
2. Sugarbaker P.H., Welch L.S., Mohamed F., and Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 12 (2003) 605-621
3. Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38 (2002) 111-121
4. Dimitrov N.V., Egner J., Balcueva E., and Suhrland L.G. High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50 (1982) 1245-1247
5. Solheim O.P., Saeter G., Finnanger A.M., and Stenwig A.E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65 (1992) 956-960
6. Djerassi I., Kim J.S., Kassarov L., et al. Response of mesothelioma to large doses of methotrexate with CF rescue used alone of with cisplatinum (abstract). Proc Am Soc Clin Oncol 4 (1985) 191
7. Vogelzang N.J., Weissman L.B., Herndon II J.E., Antman K.H., Cooper M.R., Corson J.M., et al. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12 (1994) 1436-1442
8. Kindler H.L., Belani C.P., Herndon II J.E., Vogelzang N.J., Suzuki Y., and Green M.R. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 86 (1999) 1985-1991
9. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
10. Baas P., Ardizzoni A., Grossi F., Nackaerts K., Numico G., Van Marck E., et al. EORTC Lung Cancer Group. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 39 (2003) 353-357
11. Adjei A.A. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10 (2004) 4276s-4280s
12. Thodtmann R., Depenbrock H., Dumez H., Blatter J., Johnson R.D., van Oosterom A., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17 (1999) 3009-3016
13. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 (2002) 3533-3544
14. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 (2002) 545-552
15. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
16. Bloss J., Wozniak A., Janne P., Belani C., Keohan M., Ross H., et al. Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (abstract). Proc Am Soc Clin Oncol 22 (2004) 7198
17. Karthaus M., Metzner D., Maher G., Plahl A., and Wert N. Pemetrexed+cisplatin in patients with malignant peritoneal mesothelioma (abstract). Proc Am Soc Clin Oncol 22 (2004) 7201
18. Pestieau S.R., Stuart O.A., and Sugarbaker P.H. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol 26 (2000) 696-700
19. Fizazi K., Ducreux M., Ruffie P., Bonnay M., Daniel C., Soria J.C., et al. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 18 (2000) 2293-2300
20. Fizazi K., Doubre H., Le Chevalier T., Riviere A., Viala J., Daniel C., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 (2003) 349-354
21. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al., on behalf of the European Organisation for Research and Treatment of Cancer Lung Cancer Group. National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
22. Steele J.P., Shamash J., Evans M.T., Gower N.H., Tischkowitz M.D., and Rudd R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912-3917
23. Fennell D.A., C Steele J.P., Shamash J., Sheaff M.T., Evans M.T., Goonewardene T.I., et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47 (2005) 277-281
24. Muers M.F., Rudd R.M., O'Brien M.E., Qian W., Hodson A., Parmar M.K., et al. British Thoracic Society Mesothelioma Group. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59 (2004) 144-148
25. van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85 (1999) 2577-2582
26. Kindler H.L., Millard F., Herndon II J.E., Vogelzang N.J., Suzuki Y., and Green M.R. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31 (2001) 311-317
27. Bischoff H.G., Manegold C., Knopp K., Blatter J., and Drings P. Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 17 (1998) 1784
28. Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 (1999) 25-30
29. van Haarst J.M., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86 3 (2002) 342-345
30. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 (2002) 491-496
31. Favaretto A.G., Aversa S.M., Paccagnella A., Manzini Vde P., Palmisano V., Oniga F., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97 (2003) 2791-2797
32. Kindler H.L. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 45 Suppl. 1 (2004) S125-S127
33. Bueno R., Appasani K., Mercer H., Lester S., and Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121 (2001) 225-233
34. Fennell D.A., and Rudd R.M. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5 (2004) 354-362
35. Papp T., Schipper H., Pemsel H., Bastrop R., Muller K.M., Wiethege T., et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18 (2001) 425-433